U.S. conditionally approves Zoetis' avian flu vaccine
Zoetis announced that the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) has granted the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. This vaccine is approved for use in chickens. The conditional license was issued based on demonstrated safety, purity, and a reasonable expectation of efficacy supported by serology data.
Zoetis remains dedicated to providing scientific solutions for Highly Pathogenic Avian Influenza (HPAI) to support poultry producers. The decision to vaccinate commercial poultry flocks against HPAI lies with national regulatory authorities in collaboration with the poultry industry. Previously, in 2016, Zoetis received a conditional license for its H5N1 vaccine and secured a contract award for the USDA’s National Veterinary Stockpile. This vaccine was later utilized by the U.S. Fish & Wildlife Service in 2023 to help protect California condors. Additionally, Zoetis holds a USDA license for Poulvac Flufend i AI H5N3 RG, which has been available in select international markets and was used in 2024 to safeguard endangered birds in New Zealand.
